Elysium Health Research Demonstrates Improvements in Menopause Symptoms and Estrogen Balance with Basis

Elysium Health says an open-label pilot study published in Frontiers in Aging found that seven days of supplementation with Basis, its NAD+ precursor product, was associated with reduced menopause symptom burden and a higher estradiol-to-estrone ratio. For longevity readers, the signal is not “menopause solved.” It is narrower: NAD+ metabolism may intersect with estrogen regulation in a measurable way, but the evidence remains early and structurally limited.

A short intervention, a small cohort, and a measurable endocrine signal

The study evaluated 40 healthy women over age 35. Of these, 32 self-reported symptoms associated with the menopause transition, while eight reported no or minimal symptoms. After seven days of Basis supplementation, the symptomatic group reported significant reductions in both frequency and severity of several disruptive symptoms, including hot flashes, bloating, and poor sleep.

The company’s announcement states that several of these reductions were 50% or greater. That is a clinically interesting magnitude, but the design matters. This was an open-label pilot study. Participants knew they were taking the product. Symptom outcomes were self-reported. There is no confirmed comparator arm in the provided material. Those features do not invalidate the observation, but they do constrain efficacy claims.

The more mechanistic finding is the reported increase in the estradiol-to-estrone ratio, often abbreviated E2/E1. Estradiol and estrone are two key forms of estrogen, and the study frames shifts in their balance as relevant to menopause biology. The claim here is not simply symptom modulation. It is that NAD+ precursor supplementation may be linked to a more favorable estrogen balance over a short observation window.

Why NAD+ and menopause is a serious question, not just a supplement angle

Basis is described by Elysium as its flagship product clinically proven to raise NAD+ levels. In this pilot, the company is positioning NAD+ metabolism as a possible node in reproductive aging, rather than only as a general cellular-energy marker. That is the part worth watching.

The study also characterized a previously unreported NAD+ metabolite. On its own, that finding does not establish clinical benefit. It does, however, suggest that NAD+ precursor metabolism in humans may still contain under-mapped pathways. For a field that often moves faster in marketing than in mechanistic resolution, that is a useful reminder.

Elysium also announced that Yousin Suh, Ph.D., Charles and Marie Robertson Professor of Reproductive Sciences in Obstetrics and Gynecology and Professor of Genetics and Development, and Director of the Reproductive Aging Program at Columbia University, has joined its Scientific Advisory Board. That appointment signals a stronger emphasis on women’s health and reproductive aging, an area that has historically received less systematic attention in longevity research than cardiometabolic or neurocognitive aging.

What a careful reader should track next

The immediate practical implication is not to treat a seven-day pilot as a treatment protocol. The useful takeaway is more diagnostic: future work should clarify whether the symptom signal persists, whether E2/E1 changes replicate, and whether the newly described NAD+ metabolite has functional relevance or is mainly a biochemical marker.

We would look for several features in the next study: a controlled design, longer follow-up, prespecified symptom endpoints, and clearer separation between subjective symptom reporting and biochemical change. Without those elements, the current result remains hypothesis-generating.

This is also a reminder that longevity claims increasingly behave like market signals: early data, narrative momentum, and institutional positioning can move faster than confirmatory evidence. Readers who follow volatility in other domains will recognize the pattern from analyses of speculative assets, such as an altcoin rally driven by volume signals. In biology, however, signal detection is not the same as validation.

For now, the study adds a plausible mechanistic question to the menopause and cellular-aging literature: can modulation of NAD+ metabolism influence estrogen balance during the menopause transition? The answer is not established. But the question is specific enough to deserve better-controlled testing.